Hologic Inc. ($HOLX) Stock Forecast: Up 0.3% Today

What is Hologic Inc.?

Hologic Inc. (HOLX) is a prominent company in the medical technology field, specializing in women's health, with divisions in Molecular Diagnostics, Breast Health, and GYN Surgical solutions. Today, HOLX saw a significant bullish movement in the market.

Why is Hologic Inc. going up?

HOLX stock is up 0.3% on Jan 5, 2026 17:20

• HOLX shares closed near their 52-week high, boosted by robust growth in key divisions and a proposed take-private deal, demonstrating investor confidence in the company's future.
• While HOLX lagged behind competitors like Danaher Corp. and Abbott Laboratories, its strong price performance and valuation suggest a positive outlook for current investors.
• Emphasis on precision oncology and diagnostic accuracy in healthcare, as discussed in an industry publication, may have contributed to heightened investor interest in Hologic's innovative products.
• In summary, today's bullish movement in HOLX likely stems from strong company performance, growth prospects in the sector, and potential opportunities in precision healthcare technologies.

HOLX Price Chart

HOLX Technical Analysis

HOLX News

Hologic Trading Near 52-Week High: How Should You Play the Stock?

Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

https://finviz.com/news/267052/hologic-trading-near-52-week-high-how-should-you-play-the-stock

Hologic Inc. stock underperforms Thursday when compared to competitors

Hologic Inc. (HOLX) stock underperformed on Thursday compared to its competitors, such as Danaher Corp. and Abbott Laboratories. Despite the S&P 500's daily gain, Hologic's shares closed down 0.53%, while its peers saw gains.

https://www.msn.com/en-us/money/topstocks/hologic-inc-stock-underperforms-thursday-when-compared-to-competitors/ar-AA1yyjGt?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1

RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target

RBC Capital has raised its price target for Becton, Dickinson and Company (BDX) to $210 from $202, maintaining a Sector Perform rating, based on a forecast of mid-single-digit growth and a durable core business. However, the company faces a recent lawsuit alleging anti-competitive behavior in the surgical hernia mesh market. Despite potential, the article suggests other AI stocks might offer greater upside and less risk.

https://finviz.com/news/266386/rbc-sees-durable-growth-profile-at-becton-dickinson-bdx-raises-target

Smart Oncology: 5 Stocks Chasing the $317B Prize

The precision oncology market is rapidly expanding, projected to reach $317.5 billion by 2035, driven by a shift towards biomarker-guided cancer treatments. This article highlights five companies – Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc. – that are poised to capitalize on this significant growth by focusing on diagnostic precision and therapeutic targeting.

https://www.theglobeandmail.com/investing/markets/stocks/EXAS-Q/pressreleases/36839376/smart-oncology-5-stocks-chasing-the-317b-prize/

Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?

Abbott Laboratories (ABT) shares have declined by 7.9% over the past six months, prompting investor reevaluation. The company benefits from economies of scale and robust free cash flow margins, averaging 16.8% over five years. However, its long-term revenue growth has been a mediocre 6.4% compounded annually over the same period.

https://finviz.com/news/265732/abbott-laboratories-abt-buy-sell-or-hold-post-q3-earnings

Trending Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Aave ($AAVE) Crypto Forecast: Down 5.8% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.8% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.1% Today

Solana ($SOL) Crypto Forecast: Down 5.9% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Hologic Inc. Price History

03.10.2025 - HOLX Stock was up 0.2%

• Hologic's positive movement today is linked to an $18.3B buyout deal with Blackstone and TPG, sparking optimism and confidence among investors.
• Initial market uncertainty due to a fairness investigation by a law firm has transitioned into positive market sentiment towards the deal.
• Anticipation for Hologic's upcoming Q4 earnings is boosting investor confidence, expecting favorable results and growth.
• Despite an increase in short interest, overall market sentiment favors Hologic's current trajectory.

05.00.2026 - HOLX Stock was up 0.3%

• HOLX shares closed near their 52-week high, boosted by robust growth in key divisions and a proposed take-private deal, demonstrating investor confidence in the company's future.
• While HOLX lagged behind competitors like Danaher Corp. and Abbott Laboratories, its strong price performance and valuation suggest a positive outlook for current investors.
• Emphasis on precision oncology and diagnostic accuracy in healthcare, as discussed in an industry publication, may have contributed to heightened investor interest in Hologic's innovative products.
• In summary, today's bullish movement in HOLX likely stems from strong company performance, growth prospects in the sector, and potential opportunities in precision healthcare technologies.

24.11.2025 - HOLX Stock was down 0.6%

• Today, Hologic, Inc. (HOLX) saw a significant decline in the stock market due to various factors:
• Ongoing investigations by Brodsky & Smith concerning potential breaches of fiduciary duties by the company's board.
• Positive advancements in Hologic's AI technology for mammography being overshadowed by the investigations.
• Investor concerns over governance and acquisition practices within the company.
• General market apprehension towards companies facing fiduciary duty investigations impacting Hologic's stock performance negatively.